Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 2, 2004
Event: Entry into a Material Definitive Agreement.
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on the terms of a contractual amendment.
Material Changes
On December 2, 2004, DaVita Inc. entered into an amendment and restatement of its Freestanding Dialysis Center Agreement No. 200308360 with Amgen USA Inc. Key changes include:
- Term Reduction: The agreement term is reduced by one month.
- Rebate and Discount Programs: Certain programs have been revised.
- Additional Rebates: The Company is now eligible for additional rebates.
- Termination Provisions: Certain termination clauses have been modified.
Amgen remains the Company's sole supplier of EPOGEN (Epoetin alfa) and Aranesp (darbepoetin alfa), which are used in the treatment of dialysis patients.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or a discussion of general risks and contingencies beyond the specific contractual modifications noted above. No unusual items were reported.
Investor Verification Checklist
- Verify the specific financial impact of the "additional rebates" and revised discount programs on future cost of goods sold.
- Confirm the exact new expiration date of the agreement following the one-month term reduction.
- Review the modified termination provisions to assess potential exit risks or penalties.
- Check subsequent filings for any further amendments to the Amgen supply agreement.